The direct answer: our current Wegovy prices start at €159.99 for a one-time 0.25 mg order or €143.99 with a subscription. Prices increase with the prescribed strength. At 7.2 mg, our current price is €499.99 one-time or €449.99 with a subscription. Each subscription price shown below is 10% lower than the corresponding one-time price and covers one four-week supply.
If you searched for Wegovy price Italy, you probably want more than a general pharmacy estimate. You need the price for your actual dose, what the amount includes and whether you can start treatment safely. We show our prices by strength before you begin the eligibility process. We checked every figure in this guide on 14 September 2026. Our prices, promotions, availability and destination-specific terms can change, so please confirm the live product page and checkout before ordering.
Wegovy price Italy by dose
|
Strength |
One-time price |
Subscription price |
Saving |
|---|---|---|---|
|
0.25 mg |
€159.99 |
€143.99 |
€16.00 |
|
0.5 mg |
€169.99 |
€152.99 |
€17.00 |
|
1 mg |
€179.99 |
€161.99 |
€18.00 |
|
1.7 mg |
€219.99 |
€197.99 |
€22.00 |
|
2.4 mg |
€254.99 |
€229.49 |
€25.50 |
|
7.2 mg |
€499.99 |
€449.99 |
€50.00 |
A useful Wegovy price Italy comparison must use the same strength and the same service scope. A medicine-only shelf price is not directly comparable with a treatment price that includes clinical review, prescribing when appropriate, delivery and follow-up. The table above shows our current service prices, not a national tariff set by the Italian government.
How the dose changes the price
0.25 mg is the usual starting dose. Our current price is €159.99 one-time or €143.99 by subscription. The starting dose is normally used for the first four weeks so the body can adjust before the next step is considered.
0.5 mg and 1 mg are titration steps. Our 0.5 mg prices are €169.99 one-time and €152.99 by subscription. For 1 mg, they are €179.99 and €161.99. Moving up is a clinical decision based on tolerability and response, not a way to accelerate results.
1.7 mg leads into maintenance treatment. Our current price is €219.99 one-time or €197.99 with a subscription. This strength usually follows the earlier stages of titration before 2.4 mg is considered.
2.4 mg is the standard adult maintenance dose. Our current price is €254.99 one-time or €229.49 by subscription. Some patients remain on a lower tolerated dose if their prescriber considers that more appropriate.
7.2 mg is not a routine starting option. Our current price is €499.99 one-time or €449.99 by subscription. Current European product information states that 7.2 mg may be considered for adults whose BMI was at least 30 kg/m² when treatment began, after a minimum of four weeks at 2.4 mg. If it does not provide additional clinical improvement, the dose should be reduced to 2.4 mg. Only a prescriber can decide whether this dose is suitable.
What our displayed price includes
We keep the process transparent before you submit your assessment. Our displayed treatment price includes an online clinical consultation, a prescriber review, a prescription if treatment is clinically appropriate, the medicine, delivery to eligible destinations and ongoing clinical follow-up. There is no separate consultation charge added simply to find out whether you may be suitable.
Treatment is never approved automatically. We verify identity and review the health information you provide. If Wegovy is not appropriate, a prescriber may decline treatment or discuss a different clinical approach.
One-time purchase or subscription
A one-time purchase offers flexibility if you do not want a recurring order. Our subscription reduces the listed price by 10% and is scheduled every four weeks. For example, the 0.25 mg price falls from €159.99 to €143.99, while 2.4 mg falls from €254.99 to €229.49.
The lower subscription price does not mean your dose continues unchanged without review. Weight-management treatment requires monitoring, and the dose can stay the same, increase, decrease or stop according to the prescriber's assessment. Before subscribing, check the renewal timing, cancellation terms and current destination rules on the live page.
Who may be eligible
For adults, current European product information indicates Wegovy as an addition to a reduced-calorie diet and increased physical activity for weight management when the starting BMI is at least 30 kg/m², or at least 27 kg/m² and below 30 kg/m² with at least one weight-related condition. Examples include prediabetes or type 2 diabetes, high blood pressure, abnormal blood lipids, obstructive sleep apnoea or cardiovascular disease.
Those thresholds do not guarantee approval. Your medical history, current medicines, pregnancy plans, previous reactions and other clinical factors also matter. Common adverse effects include nausea, vomiting, diarrhoea, constipation, abdominal pain and headache. Seek urgent medical advice for severe or persistent symptoms, and follow the instructions supplied with your prescribed medicine.
How to check your eligibility with us
-
Review the live price. Choose the strength only for price visibility. Your prescriber determines the clinically appropriate dose.
-
Complete the assessment. Tell us about your BMI, health conditions, current medicines and relevant medical history.
-
Wait for clinical review. We issue a prescription only when a qualified prescriber decides that treatment is appropriate.
-
Receive ongoing support. If approved and supply is available to your destination, we arrange delivery and provide follow-up during treatment.
Ready to take the next step? Check our current Wegovy prices and begin the eligibility assessment.
Comparing Wegovy with another GLP-1 option
Price should not decide which prescription treatment you use. Wegovy contains semaglutide, while Mounjaro contains tirzepatide and works through a different receptor profile. Suitability, tolerability, medical history and the prescriber's judgement matter. Read our Mounjaro versus Wegovy guide before discussing the options with a clinician.
If you now live in the United Kingdom, Rightangled provides UK-specific weight-management information and an eligibility pathway. Prices, products and prescribing rules may differ between the UK and Italy, so always use the service for your current country of residence.
Frequently asked questions
What is the lowest current Wegovy price
Our lowest current price is €143.99 for a four-week subscription supply of 0.25 mg. The equivalent one-time price is €159.99. The lowest-priced strength is normally the starting dose, not a permanent choice based on cost alone.
Why do Wegovy price Italy search results show different figures
Some pages show medicine-only pharmacy prices, while others include clinical assessment, prescribing, delivery or follow-up. Figures can also come from different dates, doses or countries. Compare the same strength, supply period and included services, then confirm the live amount before payment.
Can I select 7.2 mg because it is available
No. Availability on a price list does not establish clinical suitability. The 7.2 mg dose has specific adult eligibility and titration conditions. A prescriber must decide whether it is appropriate after assessing your response to 2.4 mg.
Does the subscription price include a prescription
Our displayed treatment price includes the consultation and a prescription when clinically appropriate. If a prescriber decides that Wegovy is unsuitable, we cannot supply it. Check the live terms for payment and refund details before ordering.
Summary
For readers comparing Wegovy price Italy options, our current prices range from €159.99 to €499.99 for a one-time four-week supply and from €143.99 to €449.99 with a subscription. The subscription is 10% lower at every listed strength. The price includes our clinical assessment, prescription when appropriate, treatment, delivery where available and follow-up.
This article provides general information and does not replace personalised medical advice. Prices were checked on 14 September 2026 and may change. Check the live product page for current pricing, availability and destination-specific terms.
Official references
